Search Results for "Neupro"

09:33 EDT 6th July 2015 | BioPortfolio

Matching Channels

None

Matching News

BRIEF-UCB advances Neupro in China

* Announced positive top-line results from two phase 3 studies evaluating Neupro in treatment of patients in China

UCB's Neupro meets in Chinese Phase III PD trial

UCB Group (Euronext:UCB) reported detailed data from a Phase III trial of Neupro rotigotine in Chinese patients with early stage Parkinson's disease (PD). The company announced top-line results in Feb...

UCB Patch Product for Parkinson's Passes China Phase III Test

UCB, the Belgian biopharma, reported positive results from a China Phase III trial of its transdermal patch product, NEUPRO®, a treatment for early stage Parkinson's disease. NEUPRO (rotigotine) i...

UCB’s Phase III results for Neupro will back filing in China this year

Belgian drugmaker UCB has announced positive top-line results from two Phase III studies of Neupro (rotigotine transdermal patch) in patients in China with early- and advanced-stage idiopathic Parkins...

BRIEF-UCB announces data from Neupro phase 3 study

* Announces first presentation of data from Neupro (rotigotine transdermal patch) phase 3 study in China at international congress

UCB to File for China Approval of Parkinson's Disease Patch

UCB of Belgium reported positive results from two China Phase III trials of Neupro, a dopamine agonist patch product, for early and advanced-stage Parkinson's disease. The company said it would comple...

Neupro rotigotine: Phase III data

UCB Full Year Report 2014: Core medicines grow by 24% while next wave of new potential solutions for patients advances

"UCB continues its growth path with Cimzia®, Vimpat® and Neupro®, now accounting for 50% of our net sales. We continue to advance and prepare the launches of our next wave of potential new patient ...

Matching PubMed Articles

None

Search Whole site using Google

Loading

Advertisement
 
Advertisement
 
Advertisement Advertisement